AN2 Therapeutics (ANTX) Accounts Payables (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Accounts Payables data on file, last reported at $2.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 14.9% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 14.9% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, down 8.92% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.6 million, down from $3.0 million in the prior quarter.
• Over the last five years, Accounts Payables for ANTX reached as high as $4.9 million in Q3 2023 and fell as low as $1.4 million in Q3 2022.
• Historically, Accounts Payables has averaged $2.6 million across 5 years, with a median of $2.6 million in 2022.
• Across the five-year window, Accounts Payables soared 238.68% in 2023 and tumbled 64.92% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $2.1 million in 2022, then advanced by 26.11% to $2.7 million in 2023, then grew by 23.95% to $3.3 million in 2024, then fell by 8.92% to $3.0 million in 2025, then fell by 13.44% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.6 million in Q1 2026, $3.0 million in Q4 2025, and $2.2 million in Q3 2025.